As of Thursday close, Global Blood Therapeutics Inc.’s (NASDAQ:GBT) stock was up $14.06, moving up 41.44 percent to $47.99. The average number of shares traded per day over the past five days has been 2,538,580 shares. 4 times new highs have been achieved over the past 5 days, with a $15.26 gain in that time frame. In the last twenty days, the average volume was 1,365,385, while in the previous 50 days, it was 1,588,306.
Since last month, GBT stock rose 43.30%. Shares of the company fell to $31.51 on 08/01/22, the lowest level in the past month. A 52-week high of $40.69 was reached on 08/04/22 after having rallying from a 52-week low of $21.65. Since the beginning of this year, GBT’s stock price has risen by 63.96% or $18.72, and marked a new high 9 times. However, the stock has increased by 17.94% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Global Blood Therapeutics Inc. (GBT) last reported insider trading activity 45 days ago on Jun 21. Svoronos Dawn, the Director of the company, disposed of 1,908 shares for $27.24 on Jun 21. It resulted in a $51,983 divestment by the insider. Pizzo Philip A. sold 1,260 shares at an average price of $27.25 on Jun 21. The insider now owns 9,112 shares following the transaction. On Sep 09, Director Morrison Scott W sold 4,800 shares at $30.21 apiece. The transaction was valued at $145,003.
The stock’s beta is 0.85. Besides these, the trailing price-to-sales (P/S) ratio of 15.41, the price-to-book (PB) ratio of 23.18.
In the three months ended March 30, Global Blood Therapeutics Inc.’s quick ratio stood at 7.70, while its current ratio was 8.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 4.34, and the total debt-to-equity ratio was 4.34. On the profitability front, the trailing twelve-month gross margin is 98.20% percent. Based on annual data, GBT earned $191.43 million in gross profit and brought in $194.75 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.10%. Return on equity (ROE) for the past 12 months was -129.70%.
In Global Blood Therapeutics Inc.’s quarter-end financial report for March 30, it reported total debt of $246.74 million against cash and short-term investments of $161.61 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. GBT’s revenue rose 29.22% to $56.1 million during the quarter, while net income inched up to $55.16 million. While analysts expected Global Blood Therapeutics Inc. to report -$1.3 quarterly earnings, the actual figure was -$1.26 per share, beating the consensus estimate by 3.10%. During the quarter, the company generated -$70.89 million in EBITDA. The liabilities of Global Blood Therapeutics Inc. were 735.54 million at the end of its most recent quarter ended March 30, and its total debt was $659.05 million. The value of shareholders’ equity is $65.1 million.
This quick technical analysis looks at Global Blood Therapeutics Inc.’s (GBT) price momentum. With a historical volatility rate of 172.06%, the RSI 9-day stood at 88.03% on 04 August.
With respect to its five-day moving average, the current Global Blood Therapeutics Inc. price is up by +46.62% percent or $15.26. At present, GBT shares trade +39.42% above its 20-day simple moving average and +72.56% percent above its 100-day simple moving average. However, the stock is currently trading approximately +79.27% above its SMA50 and +56.27% above its SMA200.
Stochastic coefficient K was 56.92% and Stochastic coefficient D was 36.45%, while ATR was 3.11. Given the Stochastic reading of 97.06% for the 14-day period, the RSI (14) reading has been calculated as 82.76%. As of today, the MACD Oscillator reading stands at 3.44, while the 14-day reading stands at 3.49.
Global Blood Therapeutics Inc. (GBT) has been rated Buy by analysts. According to 0 brokerage firms, GBT is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Global Blood Therapeutics Inc. stock as buy, with 17 recommending it as overweight.
With a median target price of $62.50, the current consensus forecast for the stock is $31.00 – $102.00. Based on these forecasts, analysts predict Global Blood Therapeutics Inc. (GBT) will achieve an average price target of $58.35.